| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $908.6K | 0.00% | 131.30K | +111% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a UPB trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 15, 2026 | Gray Michael PChief Operating Officer | Sale at price 5.49 per share. | 853 | $4.68K |
| Sep 15, 2026 | Sutherland Everett RandChief Executive Officer | Sale at price 5.49 per share. | 2.1K | $11.50K |
| Sep 15, 2026 | Houghton AdamOfficer | Sale at price 5.49 per share. | 700 | $3.84K |
| Sep 15, 2026 | Deykin AaronOfficer | Sale at price 5.49 per share. | 895 | $4.91K |
| Sep 15, 2026 | Ambrose AllisonGeneral Counsel | Sale at price 5.49 per share. | 485 | $2.66K |
| Jun 15, 2026 | Gray Michael PChief Operating Officer | Sale at price 6.10 per share. | 853 | $5.20K |
| Jun 15, 2026 | Sutherland Everett RandChief Executive Officer | Sale at price 6.10 per share. | 2.1K | $12.78K |
| Jun 15, 2026 | Houghton AdamOfficer | Sale at price 6.10 per share. | 700 | $4.27K |
| Jun 15, 2026 | Deykin AaronOfficer | Sale at price 6.10 per share. | 895 | $5.46K |
| Jun 15, 2026 | Ambrose AllisonGeneral Counsel | Sale at price 6.10 per share. | 477 | $2.91K |
| Mar 15, 2026 | Gray Michael PChief Operating Officer | Sale at price 9.29 per share. | 852 | $7.92K |
| Mar 15, 2026 | Sutherland Everett RandChief Executive Officer | Sale at price 9.29 per share. | 2.1K | $19.44K |
| Mar 15, 2026 | Houghton AdamOfficer | Sale at price 9.29 per share. | 699 | $6.49K |
| Mar 15, 2026 | Deykin AaronOfficer | Sale at price 9.29 per share. | 894 | $8.30K |
| Mar 15, 2026 | Ambrose AllisonGeneral Counsel | Sale at price 9.29 per share. | 475 | $4.41K |
| Jan 1, 2026 | Gray Michael PChief Operating Officer | Stock Award(Grant) at price 0.00 per share. | 30.5K | — |
| Jan 1, 2026 | Sutherland Everett RandChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 75K | — |
| Jan 1, 2026 | Houghton AdamOfficer | Stock Award(Grant) at price 0.00 per share. | 25K | — |
| Jan 1, 2026 | Deykin AaronOfficer | Stock Award(Grant) at price 0.00 per share. | 32K | — |
| Jan 1, 2026 | Ambrose AllisonGeneral Counsel | Stock Award(Grant) at price 0.00 per share. | 17K | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 14.5 | -75.3 | 17.2 | 2.0 | -8.9 | -17.2 | -8.8 | 4.9 | -20.4 | -32.6 | −86.9% | ||
| 2025 | -34.5 | -26.4 | -22.8 | 51.3 | -0.3 | 19.0 | 39.4 | 11.9 | 9.8 | 37.4 | 10.6 | -5.1 | +65.1% |
| 2024 | -11.8 | -24.8 | −33.7% |
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.
Buy / hold / sell counts